Point72 DIFC Ltd Sells 1,515 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

Point72 DIFC Ltd decreased its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 27.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,946 shares of the company’s stock after selling 1,515 shares during the quarter. Point72 DIFC Ltd’s holdings in Arcus Biosciences were worth $60,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System raised its stake in shares of Arcus Biosciences by 2.6% during the second quarter. Louisiana State Employees Retirement System now owns 27,500 shares of the company’s stock valued at $419,000 after acquiring an additional 700 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Arcus Biosciences by 2.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company’s stock valued at $471,000 after purchasing an additional 843 shares in the last quarter. Diversified Trust Co lifted its holdings in shares of Arcus Biosciences by 12.1% in the 2nd quarter. Diversified Trust Co now owns 13,545 shares of the company’s stock worth $206,000 after buying an additional 1,467 shares during the period. WINTON GROUP Ltd increased its stake in shares of Arcus Biosciences by 3.3% during the second quarter. WINTON GROUP Ltd now owns 59,137 shares of the company’s stock valued at $901,000 after buying an additional 1,872 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Arcus Biosciences by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 34,764 shares of the company’s stock valued at $657,000 after acquiring an additional 1,906 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcus Biosciences in a research report on Thursday, October 3rd. Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. HC Wainwright reissued a “neutral” rating and issued a $20.00 price target on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Barclays raised their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Finally, Wells Fargo & Company began coverage on shares of Arcus Biosciences in a report on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 target price for the company. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Arcus Biosciences presently has a consensus rating of “Buy” and a consensus target price of $34.00.

Arcus Biosciences Trading Up 1.0 %

Shares of NYSE:RCUS opened at $17.47 on Tuesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The firm has a market capitalization of $1.60 billion, a P/E ratio of -5.55 and a beta of 0.88. The business’s 50-day moving average is $16.42 and its 200 day moving average is $16.02. Arcus Biosciences, Inc. has a 1 year low of $13.52 and a 1 year high of $20.31.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.06. The firm had revenue of $48.00 million during the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. Arcus Biosciences’s revenue was up 50.0% on a year-over-year basis. During the same period last year, the firm posted ($0.94) EPS. On average, research analysts predict that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current fiscal year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.